Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Acceleration Mass Spectrometer for biomedicine using Vasily, Parkhomchuk, Budker Institute of Nuclear Physics Siberian Division Russian Academy of Science, Novosibirsk [email protected] Research and Practical Conference “Accelerators and Radiation technologies for the Futures of Russia” 28-29 September 2012, Saint-Petersburg Description of the solution and technology Description of technology: Isotopic marks at drug or food for investigation of dynamic distribution and decay inside body. The radioactive isotopes were first used in medicine for diagnostic procedures during the early 1930s. This eventually laid the foundation for nuclear medicine. AMS is a highly sensitive method of counting atoms. It is used to detect very low concentrations of natural isotopic abundances (typically in the range between 10-12 and 10-16of both radionuclides and stable nuclides. The main advantages of AMS compared to conventional radiometric methods are the use of smaller samples (mg and even sub-mg size) and shorter measuring times (less than 1 hr). The remarkable sensitivity of AMS opens the way to a host of other new diagnostic tests as well: assays for early detection of various disorders, tests that determine the efficacy of therapeutic regimens, studies of how the body handles various nutrients and vitamins, and assessment of the effects of environmental substances and toxins. When combined with such imaging technologies as magnetic resonance imaging, accelerator mass spectrometry will be able to assess changes in tissues, hormone levels, and metabolites in real time. In the biochemical field, synthesized 14C labeled compounds can be administered as a tracer dose for in-vivo human metabolic and drug studies which require AMS analysis of graphitized biological samples Research and Practical Conference “Accelerators and Radiation technologies for the Futures of Russia” 28-29 September 2012, Saint-Petersburg Current condition and prospects of development: ref. units 10 0 10 -1 10 -2 10 -3 10 -4 10 -5 10 -6 10 -7 10 -8 10 -9 10 -10 10 -11 10 -12 10 -13 10 -14 10 -15 10 -16 11 First AMS prototype was made 14 M at BINP 2009 Fig show low energy spectra M12 =1, M 14 =10-14 molecular ions 14 C modern sample But after pass AMS and clearing "dead" sample 12 13 14 mass 15 16 molecular ion, 17 Sample from modern tree M 14 =10-12 clear viseable Research and Practical Conference “Accelerators and Radiation technologies for the Futures of Russia” 28-29 September 2012, Saint-Petersburg Description of the solution Description of novelty: in brief (short) arguments of novelty Current condition and prospects of development: current status and planned steps that will be created as a result of R & D The potential for building a relationship with one of the world leaders company in the project implementation on the world market: it depend from development our equipments. Good design and high level reliability can open windows for collaborations Compact AMS for 6*9 m*m room Sample measuring rate about 200/day Preliminary prise 3M$ Research and Practical Conference “Accelerators and Radiation technologies for the Futures of Russia” 28-29 September 2012, Saint-Petersburg Market On what market segment is focused your product- biology, pharmaceutical industry, ecology, safety systems- food, water, industry isotopic marking Current solutions in the market and the key advances or uniqueness of your product Potential consumers of the product (target). List of your product users, consumers (5-10 companies)- Demand on your product on market segment (pcs, unit) 2014 – 2025 10 units/year Assessment of the global market, All market now about 10-30/year Price about 3 M$/unit 30-90 M$/year Research and Practical Conference “Accelerators and Radiation technologies for the Futures of Russia” 28-29 September 2012, Saint-Petersburg Investor of the project realization (implementation) Привлеченные инвесторы или, если инвестор не привлечен, то для каких компаний, фондов, частных лиц и др. по мнению Разработчика проект может п Existing investors. In case if there is not investor, for which companies, foundations, individuals, and others according to the project developer opinion could be promoted as commercial interest Can order about 10 units for biomedicine using inside former USSR counties Research and Practical Conference “Accelerators and Radiation technologies for the Futures of Russia” 28-29 September 2012, Saint-Petersburg Cooperation for the project Is not clear now. Inside Russia exist few institutes that interested collaboration of this technology. From other countries it was few discussions on conferences Research and Practical Conference “Accelerators and Radiation technologies for the Futures of Russia” 28-29 September 2012, Saint-Petersburg Project team Budker Institute of Nuclear Physics Parkhomchuk V.V., RastegeevS.A. R&D, production of prototype First experiments with samples Institute of Catalyze Okunev A.G. Sample productions Novosibirsk State University Bondar A.E. Guliaeva L.F. Biomedicine experiment on existing Education specialists at NGU Research and Practical Conference “Accelerators and Radiation technologies for the Futures of Russia” 28-29 September 2012, Saint-Petersburg